• Deanna S Cross, Alanna Kulchak Rahm, Tia L Kauffman, Jennifer Webster, Anh Quynh Le, Heather Spencer Feigelson, Gwen Alexander, Paul Meier, Adedayo A Onitilo, Pamala A Pawloski, Andrew E Williams, Stacey Honda, Yeehwa Daida, Catherine A McCarty, Katrina A B Goddard, and CERGEN study team.
• Marshfield Clinic Research Foundation, Marshfield, Wisconsin, USA.
• Genet. Med. 2013 Dec 1; 15 (12): 933-40.

PurposeThe aim of this study was to examine Lynch syndrome screening of patients with metastatic colorectal cancer in integrated health-care-delivery organizations.MethodsWe determined the availability of Lynch syndrome screening criteria and actual Lynch syndrome screening in the medical records of 1,188 patients diagnosed with metastatic colorectal cancer between 2004 and 2009 at seven institutions in the Cancer Research Network.ResultsWe found infrequent use of Lynch syndrome screening (41/1,188). Family history was available for 937 of the 1,188 patients (79%). There was sufficient information to assess Lynch syndrome risk using family history-based criteria in 719 of the 937 patients (77%) with family history documentation. In 391 individuals with a family history of a Lynch syndrome-associated cancer, 107 (27%) could not be evaluated due to missing information such as age of cancer onset. Eleven percent of patients who met the Bethesda criteria and 25% of individuals who met the Amsterdam II criteria were screened for Lynch syndrome. Recommended guidelines were adhered to during screening, but no testing method was preferred.ConclusionThe information required for Lynch syndrome screening decisions is routinely collected but seldom used. There is a critical gap between collection of family history and its use to guide Lynch syndrome screening, which may support a case for implementation of universal screening guidelines.

19 keywords...

hide…